New FDA-Approved Pill Lowers High Blood Pressure and May Slow Kidney Disease

The FDA approved AstraZeneca’s Baxfendy, or baxdrostat, in May 2026 for adults whose high blood pressure remains uncontrolled despite existing treatment. In a Phase 3 trial of 796 patients, the 2 mg dose lowered systolic pressure by an average of 15.7 mm Hg after 12 weeks, compared with 5.8 mm Hg for placebo. Earlier research found a reduction in a marker of kidney damage, but effects on disease progression remain under study.
Ad
0Like0Dislike0Comments0Shares






Comments 0
No comments yet. Be the first to share your view in the app.
Join the discussion: comments and votes are in the free Beloud app.